Eli Lilly Invests Billions in Next-Generation Gene Therapy Platform
Published on 02/11/2026 at 22:01 | Redaktion boerse-global.de
While Eli Lilly continues to generate headlines and record earnings with its blockbuster weight-loss drugs, the pharmaceutical giant’s leadership is strategically deploying that capital. In a move valued at up to $2.4 billion, the company is acquiring Orna Therapeutics, a Massachusetts-based biotech firm, to gain a deep foothold in the evolving field of genetic medicine. The acquisition, announced on February 9th, aims to fundamentally simplify complex treatments for autoimmune conditions and broaden Lilly’s long-term portfolio.
This deal is part of a clear strategic initiative. Eli Lilly is leveraging the substantial revenue from its GLP-1 weight-loss business to reduce its dependence on any single therapeutic area. The financial capacity for such ambitious Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
